Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients

Critical Care

Volumn 21, Issue 1, 2017, Pages

  Russell, James A ^a   Vincent, Jean Louis ^b   Kjølbye, Anne Louise ^c   Olsson, Håkan ^c   Blemings, Allan ^c   Spapen, Herbert ^d   Carl, Peder ^e   Laterre, Pierre Francois ^f   Grundemar, Lars ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Ferring Pharmaceuticals AS   (Denmark)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e HVIDOVRE HOSPITAL   (Denmark)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Fluid balance; Mechanical ventilation; Norepinephrine; Selepressin; Septic shock; V1A agonist

Indexed keywords

NORADRENALIN; PLACEBO; SELEPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; ATRIAL FIBRILLATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYANOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUID BALANCE; FLUID RESUSCITATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLACTATEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; MYOCARDITIS; PERIPHERAL ISCHEMIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTIC SHOCK; ADOLESCENT; AGED; AGONISTS; BELGIUM; CHILD; CLINICAL TRIAL; COMPLICATION; DENMARK; HYPOTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; UNITED STATES;

ADOLESCENT; ADULT; AGED; BELGIUM; CHILD; DENMARK; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; NOREPINEPHRINE; PLACEBOS; RECEPTORS, VASOPRESSIN; SHOCK, SEPTIC; UNITED STATES; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 85027262855     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-017-1798-7     Document Type: Article

References (28)

1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486-552.
2. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001;27(8):1416-21.
3. Landry DW, Levin HR, Gallant EM, Ashton Jr RC, Seo S, D'Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95(5):1122-5.
4. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96(3):576-82.
5. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-87.
6. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509-18.
7. Hsu JL, Liu V, Patterson AJ, Martin GS, Nicolls MR, Russell JA. Potential for overuse of corticosteroids and vasopressin in septic shock. Crit Care. 2012;16(5):447.
8. 1A receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med. 2016;44(1):23-31.
9. Maybauer MO, Maybauer DM, Enkhbaatar P, Laporte R, Wiśniewska H, Traber LD, et al. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med. 2014;42(7):e525-33.
10. 1a receptor agonism in ovine septic shock. Crit Care Med. 2011;39(1):119-25.
11. 1a agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circ Physiol. 2012;303(10):H1245-54.
12. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-75.
13. Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011;39(2):259-65.
14. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34(2):344-53.
15. Murphy CV, Schramm GE, Doherty JA, Reichley RM, Gajic O, Afessa B, et al. The importance of fluid management in acute lung injury secondary to septic shock. Chest. 2009;136(1):102-9.
16. Ball SG. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Ann Clin Biochem. 2007;44(Pt 5):417-31.
17. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1(4):682-9.
18. Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost. 2003;1(4):821-8.
19. O'Connor PM, Cowley Jr AW. Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway. Am J Physiol Renal Physiol. 2007;293(2):F526-32.
20. Morelli A, Ertmer C, Pietropaoli P, Westphal M. Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock. Expert Opin Pharmacother. 2009;10(15):2569-75.
21. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Cecchini V, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009;13(4):R130.
22. 1a receptor full agonist for the treatment of vasodilatory hypotension. J Pharmacol Exp Ther. 2011;337(3):786-96.
23. 1a receptor agonists. J Med Chem. 2011;54(13):4388-98.
24. The ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370(18):1683-93.
25. Asfar P, Russell JA, Tuckermann J, Radermacher P. Selepressin in septic shock: a step toward decatecholaminization? Crit Care Med. 2016;44(1):234-6.
26. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol. 1989;256(2 Pt 2):F274-8.
27. Stolk RF, van der Poll T, Angus DC, van der Hoeven JG, Pickkers P, Kox M. Potentially inadvertent immunomodulation: norepinephrine use in sepsis. Am J Respir Crit Care Med. 2016;194(5):550-8.
28. Gordon AC, Wang N, Walley KR, Ashby D, Russell JA. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest. 2012;142(3):593-605.